Sensus Healthcare

Sensus manufactures the SRT-100 family, offering superficial radiation therapy as a non-surgical alternative to Mohs surgery for basal cell carcinoma, squamous cell carcinoma and keloids. 

SRT delivers calibrated low-energy X-ray beams penetrating approximately 5mm below skin surface, destroying malignant cells while preserving healthy tissue. Treatment requires no cutting, bleeding, anaesthesia, stitches or reconstruction with minimal infection risk. 

SRT-100 Vision features integrated high-frequency ultrasound, volumetric tumour analysis, beam margin planning and embedded dosimetry for image-guided therapy. The compact system has 30” x 30” footprint with automatic filters, auto warm-up and applicator sensing. FDA cleared for NMSC and keloids, the system holds approvals across world markets, including the UK.